Bibliographic Details
| Title: |
Structure-based classification predicts drug response in EGFR-mutant NSCLC. |
| Authors: |
Robichaux, Jacqulyne P., Le, Xiuning, Vijayan, R. S. K., Hicks, J. Kevin, Heeke, Simon, Elamin, Yasir Y., Lin, Heather Y., Udagawa, Hibiki, Skoulidis, Ferdinandos, Tran, Hai, Varghese, Susan, He, Junqin, Zhang, Fahao, Nilsson, Monique B., Hu, Lemei, Poteete, Alissa, Rinsurongkawong, Waree, Zhang, Xiaoshan, Ren, Chenghui, Liu, Xiaoke |
| Source: |
Nature; 9/30/2021, Vol. 597 Issue 7878, p732-737, 6p |
| Abstract: |
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)1–3. Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations4–6. However, effective therapies have not been identified for additional EGFR mutations. Furthermore, the frequency and effects of atypical EGFR mutations on drug sensitivity are unknown1,3,7–10. Here we characterize the mutational landscape in 16,715 patients with EGFR-mutant NSCLC, and establish the structure–function relationship of EGFR mutations on drug sensitivity. We found that EGFR mutations can be separated into four distinct subgroups on the basis of sensitivity and structural changes that retrospectively predict patient outcomes following treatment with EGFR inhibitors better than traditional exon-based groups. Together, these data delineate a structure-based approach for defining functional groups of EGFR mutations that can effectively guide treatment and clinical trial choices for patients with EGFR-mutant NSCLC and suggest that a structure–function-based approach may improve the prediction of drug sensitivity to targeted therapies in oncogenes with diverse mutations.Structural classification of mutations in the epidermal growth factor receptor causing non-small cell lung cancer is a better predictor of patient outcomes following drug treatment than traditional exon-based classification. [ABSTRACT FROM AUTHOR] |
|
Copyright of Nature is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
